Clinical Trial Update: An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating nivolumab in combination with rucaparib, docetaxel, or enzalutamide in metastatic castration-resistant prostate cancer has completed, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)
• Rubraca (rucaparib) (rucaparib)
• Taxotere (docetaxel) (docetaxel)
• Xtandi (enzalutamide) (enzalutamide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-09